Free Trial
NASDAQ:EOLS

Evolus (EOLS) Stock Price, News & Analysis

Evolus logo
$6.75 -0.07 (-1.03%)
Closing price 04:00 PM Eastern
Extended Trading
$6.75 0.00 (0.00%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Evolus Stock (NASDAQ:EOLS)

Advanced

Key Stats

Today's Range
$6.72
$6.89
50-Day Range
$5.98
$7.68
52-Week Range
$5.71
$17.44
Volume
357,928 shs
Average Volume
1.07 million shs
Market Capitalization
$436.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25
Consensus Rating
Hold

Company Overview

Evolus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

EOLS MarketRank™: 

Evolus scored higher than 75% of companies evaluated by MarketBeat, and ranked 199th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Evolus has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Evolus has a consensus price target of $21.25, representing about 214.8% upside from its current price of $6.75.

  • Amount of Analyst Coverage

    Evolus has only been the subject of 4 research reports in the past 90 days.

  • Read more about Evolus' stock forecast and price target.
  • Earnings Growth

    Earnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evolus is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evolus is -6.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Evolus has a P/B Ratio of 75.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Evolus' valuation and earnings.
  • Percentage of Shares Shorted

    24.92% of the float of Evolus has been sold short.
  • Short Interest Ratio / Days to Cover

    Evolus has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Evolus has recently increased by 8.75%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Evolus does not currently pay a dividend.

  • Dividend Growth

    Evolus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.92% of the float of Evolus has been sold short.
  • Short Interest Ratio / Days to Cover

    Evolus has a short interest ratio ("days to cover") of 9.3.
  • Change versus previous month

    Short interest in Evolus has recently increased by 8.75%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Evolus this week, compared to 5 articles on an average week.
  • Search Interest

    5 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Evolus insiders have bought 376.12% more of their company's stock than they have sold. Specifically, they have bought $204,600.00 in company stock and sold $42,972.00 in company stock.

  • Percentage Held by Insiders

    Only 5.90% of the stock of Evolus is held by insiders.

  • Percentage Held by Institutions

    90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Evolus' insider trading history.
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EOLS Stock News Headlines

Evolus to Report Third Quarter Financial Results on November 5, 2025
Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
See More Headlines

EOLS Stock Analysis - Frequently Asked Questions

Evolus' stock was trading at $11.04 at the start of the year. Since then, EOLS stock has decreased by 38.9% and is now trading at $6.75.

Evolus, Inc. (NASDAQ:EOLS) announced its quarterly earnings results on Tuesday, March, 23rd. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The firm earned $20.58 million during the quarter, compared to analyst estimates of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 759.04% and a negative net margin of 22.31%.
Read the conference call transcript
.

Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus' top institutional shareholders include Rice Hall James & Associates LLC (1.81%), Assenagon Asset Management S.A. (0.44%), Pure Financial Advisors LLC (0.03%) and Global Retirement Partners LLC (0.02%). Insiders that own company stock include Alphaeon 1 Llc, Medytox Inc, David Moatazedi, Rui Avelar, Vikram Malik, Sandra Beaver, Tomoko Yamagishi-Dressler, Brady Stewart, Albert G White III, David N Gill and David N Gill.
View institutional ownership trends
.

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
3/23/2021
Today
10/23/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EOLS
CIK
1570562
Fax
N/A
Employees
170
Year Founded
2014

Price Target and Rating

High Price Target
$25.00
Low Price Target
$18.00
Potential Upside/Downside
+215.0%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.42 million
Net Margins
-22.31%
Pretax Margin
-22.05%
Return on Equity
-759.04%
Return on Assets
-24.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.27
Quick Ratio
1.86

Sales & Book Value

Annual Sales
$266.27 million
Price / Sales
1.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.09 per share
Price / Book
74.94

Miscellaneous

Outstanding Shares
64,680,000
Free Float
60,869,000
Market Cap
$436.27 million
Optionable
Optionable
Beta
1.04

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:EOLS) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners